Cost-effectiveness of prescreening versus empirical vaccination for hepatitis A in Egyptian children with chronic liver disease.
The aim of the study was to determine the prevalence of anti-hepatitis A virus (anti-HAV) antibodies among 172 children with chronic liver disease, and to calculate the cost-effectiveness of prescreening prior to hepatitis A vaccination. Anti-HAV antibodies were positive in 85.1%. However, seroprevalence of anti-HAV antibodies was 62.1% in children < 5 years and 94.4% in children 5+ years. We conclude that while it is cost-effective to do prescreening before hepatitis A vaccination for children with chronic liver disease aged 5+ years, prescreening might not be cost-effective in those aged < 5 years.
El-Karaksy
H
H
Department of Paediatrics, University of Cairo, Cairo, Egypt. hanaakaraksy@yahoo.com
El-Sayed
R
R
El-Raziky
M
M
El-Koofy
N
N
Mansour
S
S
D017677:Age Distribution; D000367:Age Factors; D016022:Case-Control Studies; D016009:Chi-Square Distribution; D002648:Child; D002675:Child, Preschool; D002908:Chronic Disease; D003362:Cost-Benefit Analysis; D004534:Egypt / Q000453:epidemiology; D006287:Health Planning Guidelines; D006506:Hepatitis A / Q000150:complications / Q000175:diagnosis* / Q000453:epidemiology / Q000517:prevention & control*; D035922:Hepatitis A Antibodies / Q000097:blood; D006801:Humans; D017589:Immunization Programs; D008107:Liver Diseases / Q000821:virology*; D008403:Mass Screening / Q000191:economics* / Q000379:methods; D011159:Population Surveillance; D015397:Program Evaluation; D016036:Seroepidemiologic Studies; D014611:Vaccination / Q000191:economics* / Q000379:methods
D035922:Hepatitis A Antibodies